Pilot Study: Interest of Belatacept As a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients At Risk of Chronic Renal Failure (BELACOEUR)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 6, 2020

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions

Heart Transplant Failure

Interventions

DRUG

Belatacept Injection

9 injections of belatacept at 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months 11 months and 12 months post graft

Trial Locations (4)

RECRUITING

Karine Nubret, Bordeaux

RECRUITING

Laurent Sebbag, Lyon

RECRUITING

Claire Garandeau, Nantes

RECRUITING

Bertrand Lelong, Rennes

All Listed Sponsors

lead

Nantes University Hospital

OTHER